

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 March 2025 (13.03.2025)



(10) International Publication Number
WO 2025/054560 A3

(51) International Patent Classification:
C07D 491/22 (2006.01) A61P 35/00 (2006.01)
A61K 47/68 (2017.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2024/045733

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(22) International Filing Date:
06 September 2024 (06.09.2024)

(25) Filing Language: English

(26) Publication Language: English

(88) Date of publication of the international search report:
24 April 2025 (24.04.2025)

(30) Priority Data:
63/581,306 08 September 2023 (08.09.2023) US
63/591,078 17 October 2023 (17.10.2023) US
63/550,023 05 February 2024 (05.02.2024) US

(71) Applicant: NEXTPOINT THERAPEUTICS, INC.
[US/US]; 238 Main Street, 5th Floor, Cambridge, Massa-
chusetts 02142 (US).

(72) Inventors: ETEMAD-GILBERTSON, Bijan; c/o Next-
Point Therapeutics, Inc., 238 Main Street, 5th Floor, Cam-
bridge, Massachusetts 02142 (US). CHARI, Ravi; c/o
NextPoint Therapeutics, Inc., 238 Main Street, 5th Floor,
Cambridge, Massachusetts 02142 (US).

(74) Agent: LI, Xiaodong et al.; CHOATE, HALL & STE-
WART LLP, Two International Place, Boston, Massachu-
setts 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: ANTIBODY-DRUG CONJUGATES

(57) Abstract: Among other things, the present disclosure provides conjugates comprising target binding moieties, payload moieties and linkers. In some embodiments, the present disclosure provides pharmaceutical compositions comprising provided conjugates. In some embodiments, the present disclosure provides methods for preventing or treating various conditions, disorders or diseases using provided conjugates and compositions thereof. In some embodiments, the present disclosure provides technologies for manufacturing provided conjugates and compositions thereof.

WO 2025/054560 A3